KACTUS

Deliver quality recombinant proteins and GMP enzymes with a commitment to reliability, speed, and innovation.

Founded in March 2018, KACTUS began with a mission to deliver innovative recombinant protein solutions that address the unmet needs of researchers and the challenges of complex protein expression. The company quickly made its mark by becoming the first to successfully express the full-length multi-transmembrane protein Claudin 18.2 in July 2018, demonstrating its robust protein engineering capabilities. In 2019, KACTUS introduced the Structure-Aided Multiplex Screening (SAMS™) technology platform, which enhanced their ability to express complex proteins.

By 2020, KACTUS had established a cGMP-compliant enzyme manufacturing facility, providing GMP-grade mRNA and gene editing enzymes. Their commitment to regulatory compliance was further demonstrated in 2021 with successful GMP audits and Drug Master File submissions. In February 2022, KACTUS expanded its global operational footprint to improve product accessibility and customer service.

In December 2022, a major milestone was achieved when its GMP-grade CRISPR-Cas9 enzyme was approved for use in a clinical trial for beta-thalassemia, demonstrating the credibility of its GMP manufacturing facilities. In November 2023, KACTUS launched AccuBase®, the first commercially available base editor, revolutionizing precision gene editing. In July 2024, they expanded their transmembrane protein display platforms to include nanodiscs, further helping customers overcome membrane protein display challenges.

Today, KACTUS offers more than 3000 recombinant proteins, more than 25 GMP enzymes, and custom protein expression services. They continue to innovate by focusing on today’s R&D and commercialization challenges to facilitate novel drug development.

Product Portfolio

• Target Antigens for Drug Discovery
  • Bioactive target antigens for drug discovery campaigns.
• Gene Editing Products
  • GMP-Grade gene editing enzymes and AAV Titration ELISA Kits.
• RNA Enzymes
  • GMP-grade mRNA production enzymes.
• MHC Tetramers & Monomers
  • MHC-peptide complexes and peptide-ready MHCs.
• Cell Therapy Products
  • CAR-T Targets, Laminin 521, Cytokines, & more.